Status:
UNKNOWN
Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Conditions:
Bronchiectasis Adult
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Airflow limitation is common exist in idiopathic bronchiectasis patients. However, there are few evidence on the treatment of bronchodilator in bronchiectasis with airflow limitation. The efficacy and...
Detailed Description
Airflow limitation is common exist in idiopathic bronchiectasis patients. Our previous studies showed that FEV1\<50% is one of the major risk factors for poor prognosis and high incidence of acute exa...
Eligibility Criteria
Inclusion
- Idiopathic bronchiectasis with FEV1/FVC \< 70%
Exclusion
- With Asthma
- α-1 antitrypsin deficiency
- Turculosis
- Lung cancer
- Sarcoidosis
- Idiopathic pulmonary fibrosis
- Primary pulmonary hypertension
- Uncontrolled sleep apnea
- Bronchiectasis accepted long-term low dose macrolides
- Pulmonary surgery within 6 months
- Lower respiratory tract infections require antibiotic treatment in 6 weeks
- Upper respiratory tract infection did not recover for at least 7 days
- With Glaucoma or severe prostate hyperplasia that can not use Indacaterol
- Patients allergic to experimental drugs
- Women pregnant, breast-feeding or who planned a pregnancy during the study
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04509661
Start Date
September 1 2020
End Date
June 1 2024
Last Update
August 12 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.